EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Loss of CEACAM1 in hepatocytes causes hepatic fibrosis

Sobia Zaidi, Suman Asalla, Harrison T Muturi, Lucia Russo, Raziyeh Abdolahipour, Getachew Debas Belew, Maria Benitez Iglesias, Mary Feraudo, Lensay Leon, Enoch Kuo, Xiuli Liu, Sivarajan Kumarasamy und 5 weitere

European Journal of Clinical Investigation · 2024

DOI: 10.1111/eci.14177 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Investigation, 2024. Verfasst von Sobia Zaidi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio, USA. Hauptthemen laut MEDLINE: Hepatocytes, Insulin Resistance, Liver Cirrhosis, CEACAM1 Protein. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, NIMHD NIH HHS, Foundation for the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The role of insulin resistance in hepatic fibrosis in Metabolic dysfunction‐Associated SteatoHepatitis (MASH) remains unclear. Carcinoembryonic Antigen‐related Cell Adhesion Molecule1 protein (CEACAM1) promotes insulin clearance to maintain insulin sensitivity and repress de novo lipogenesis, as bolstered by the development of insulin resistance and steatohepatitis in AlbuminCre + Cc1 fl/fl mice with liver‐specific mouse gene encoding CEACAM1 protein (Ceacam1) deletion. We herein investigated whether these mice also developed hepatic fibrosis and whether hepatic CEACAM1 is reduced in patients with MASH at different fibrosis stages.

Methods

AlbuminCre + Cc1 fl/fl mice were fed a regular or a high‐fat diet before their insulin metabolism and action were assessed during IPGTT, and their livers excised for histochemical, immunohistochemical and Western blot analysis. Sirius red staining was used to assess fibrosis, and media transfer was employed to examine whether mutant hepatocytes activated hepatic stellate cells (HSCs). Hepatic CEACAM1 protein levels in patients with varying disease stages were assessed by ELISA.

Results

Hepatocytic deletion of Ceacam1 caused hyperinsulinemia‐driven insulin resistance emanating from reduced hepatic insulin clearance. AlbuminCre + Cc1 fl/fl livers showed inflammation, fibrosis and hepatic injury, with more advanced bridging and chicken‐wire hepatic fibrosis under high‐fat conditions. Media transferred from hepatocytes isolated from mutant mice activated control HSCs, likely owing to their elevated endothelin1 content. Interestingly, hepatic CEACAM1 levels were lower in the livers of patients with MASH and declined gradually with advanced fibrosis stage.

Conclusions

Hepatic CEACAM1 levels declined with progression of MASH in humans. The phenotype of AlbuminCre + Cc1 fl/fl mice assigned a key role to CEACAM1 loss from hepatocytes in hepatic fibrosis independently of other liver cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HepatocytesInsulin ResistanceLiver CirrhosisCEACAM1 ProteinAnimalsHumansMaleMiceAntigens, CDCarcinoembryonic AntigenCell Adhesion MoleculesDiet, High-FatFatty LiverHepatic Stellate CellsHyperinsulinismNon-alcoholic Fatty Liver Disease

Stichwörter der Autor:innen

fibrosis stagehepatic stellate cellsinsulin extractioninsulin resistancesteatohepatitis

Substanzen

Antigens, CDCarcinoembryonic AntigenCD66 antigensCeacam1 protein, mouseCell Adhesion MoleculesCEACAM1 Protein

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio, USA.
  • Department of Surgery, College of Medicine, University of Florida, Gainesville, Florida, USA.
  • Center for Diabetes and Endocrine Research (CeDER), College of Medicine and Life Sciences, University of Toledo, Toledo, Ohio, USA.
  • Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
  • Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri, USA.
  • Diabetes Institute, Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio, USA.

ORCID-Profile: Sonia M Najjar

Förderung

  • NIDDK NIH HHS
  • NIMHD NIH HHS
  • Foundation for the National Institutes of Health
  • NHLBI NIH HHS

Zitieren

APA

Zaidi, S., Asalla, S., Muturi, H. T., Russo, L., Abdolahipour, R., Belew, G. D., Iglesias, M. B., Feraudo, M., Leon, L., Kuo, E., Liu, X., Kumarasamy, S., Ghadieh, H. E., Gatto-Weis, C., Zarrinpar, A., Duarte, S., & Najjar, S. M. (2024). Loss of CEACAM1 in hepatocytes causes hepatic fibrosis. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14177

Vancouver

Zaidi S, Asalla S, Muturi HT, Russo L, Abdolahipour R, Belew GD, et al. Loss of CEACAM1 in hepatocytes causes hepatic fibrosis. European Journal of Clinical Investigation. 2024. doi:10.1111/eci.14177

BibTeX
@article{Zaidi2024,
  author = {Zaidi, Sobia and Asalla, Suman and Muturi, Harrison T and Russo, Lucia and Abdolahipour, Raziyeh and Belew, Getachew Debas and Iglesias, Maria Benitez and Feraudo, Mary and Leon, Lensay and Kuo, Enoch and Liu, Xiuli and Kumarasamy, Sivarajan and Ghadieh, Hilda E and Gatto-Weis, Cara and Zarrinpar, Ali and Duarte, Sergio and Najjar, Sonia M},
  title = {Loss of CEACAM1 in hepatocytes causes hepatic fibrosis},
  journal = {European Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1111/eci.14177}
}
Kostenlos starten →